Currently, intravitreal injections of anti-VEGF agents, ranibizumab (Lucentis®, Novartis Pharma AG, Basel, Switzerland) and aflibercept (Eylea®, Bayer, Leverkusen, Germany), or steroids, dexamethasone implant (DEX-implant, Ozurdex®, AbbVie, North Chicago, IL, USA) and fluocinolone acetonide implant (FAc-implant, Iluvien®, Alimera Sciences Ltd., Alpharetta, GA, USA), are considered to be the standard of care for treating DME [3,4,5], and act by reducing the macular edema caused by the disease. The gene discussed is VEGFA; the disease is macular retinal edema.